MAM
ADMS

Meeder Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Meeder Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,763
Closed -$5K – 2651
2020
Q1 		$5K Buy
+1,763
New +$7.9K ﹤0.01% 1833
2019
Q4 		– Sell
-972
Closed -$5K – 2489
2019
Q3 		$5K Buy
+972
New +$6K ﹤0.01% 1790
2018
Q1 		– Sell
-319
Closed -$11K – 1805
2017
Q4 		$11K Buy
319
+33
+12% +$921 ﹤0.01% 1112
2017
Q3 		$6K Buy
286
+194
+211% +$3.56K ﹤0.01% 1231
2017
Q2 		$2K Sell
92
-149
-62% -$2.46K ﹤0.01% 1454
2017
Q1 		$4K Buy
+241
New +$4.11K ﹤0.01% 1210

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Meeder Asset Management's ADMS Position: Q2 2020 in Review

Meeder Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q2 2020, closing a stake of 1,763 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in ADMS in Q1 2017 and held it in 6 quarters. The position peaked at $11K in Q4 2017. 61 funds tracked by Wall St. Rank hold ADMS as of Q2 2020.

  • Meeder Asset Management reported no remaining Adamas Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 1,763 Adamas Pharmaceuticals shares in Q2 2020, an estimated $5K.
  • Meeder Asset Management first reported a position in Adamas Pharmaceuticals in Q1 2017 and held it in 6 quarters.
  • Meeder Asset Management's Adamas Pharmaceuticals position peaked at $11K in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.